Wenwen Zhang 1 , Zhaojun Shen 1 , Hui Luo 1 , Xiaoli Hu 1 , Lihong Zheng 1 , Xueqiong Zhu 2 Show Affiliations »
Abstract
BACKGROUND: Ovarian cancer is the leading cause of deaths attributable to gynecologic malignancies. Late diagnosis and a high tendency of metastasis and drug resistance often lead to recurrence and poor outcomes. Anti-angiogenesis is considered a promising therapeutic strategy for recurrent ovarian cancers. Anti-VEGF body, bevacizumab, is an angiogenesis inhibitor with demonstrated activity and tolerable toxicity. OBJECTIVE: To elucidate the benefits and side effects of bevacizumab for the therapy of recurrent ovarian cancer. METHODS: Reviewed the results of published clinical trials. RESULTS: Recent Phase II studies indicated that bevacizumab monotherapy or in combination with conventional or other anti-angiogenic chemotherapy reagents could be effective for recurrent (platinum- sensitive and -resistant) ovarian cancers. Additionally, two phase III randomized trials reached similar conclusions that in either platinum-sensitive or -resistant ovarian cancers, adding bevacizumab to chemotherapy can improve progression-free survival. Despite the general recognition of bevacizumab as a well-tolerated drug in recurrent ovarian cancer patients, oncologists have become aware of the significant risks associated with gastrointestinal perforation. CONCLUSION: Bevacizumab used alone or combined with other chemotherapy reagents is efficacious and tolerable in the treatment of recurrent ovarian cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: Ovarian cancer is the leading cause of deaths attributable to gynecologic malignancies . Late diagnosis and a high tendency of metastasis and drug resistance often lead to recurrence and poor outcomes. Anti-angiogenesis is considered a promising therapeutic strategy for recurrent ovarian cancers . Anti-VEGF body, bevacizumab , is an angiogenesis inhibitor with demonstrated activity and tolerable toxicity . OBJECTIVE: To elucidate the benefits and side effects of bevacizumab for the therapy of recurrent ovarian cancer . METHODS: Reviewed the results of published clinical trials. RESULTS: Recent Phase II studies indicated that bevacizumab monotherapy or in combination with conventional or other anti-angiogenic chemotherapy reagents could be effective for recurrent (platinum - sensitive and -resistant) ovarian cancers . Additionally, two phase III randomized trials reached similar conclusions that in either platinum -sensitive or -resistant ovarian cancers , adding bevacizumab to chemotherapy can improve progression-free survival. Despite the general recognition of bevacizumab as a well-tolerated drug in recurrent ovarian cancer patients , oncologists have become aware of the significant risks associated with gastrointestinal perforation. CONCLUSION: Bevacizumab used alone or combined with other chemotherapy reagents is efficacious and tolerable in the treatment of recurrent ovarian cancer . Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Chemical
Disease
Gene
Species
Keywords:
Bevacizumab; chemotherapy; efficacy; ovarian cancer; recurrent; safety
Mesh： See more »
Substances： See more »
Year: 2017
PMID： 27138763 DOI： 10.2174/1389450117666160502150237
Source DB: PubMed Journal: Curr Drug Targets ISSN： 1389-4501 Impact factor: 3.465